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ABSTRACT By definition, mucosal melanomas are malignant primary 
tumors originating from melanocytes located in the mucosal mem-
branes of the nasal cavity and accessory sinuses, oral cavity, lips and 
pharynx, and vulvar, vaginal or uterus, anorectal, or basically any other 
part of the mucosal surface lining. These malignant melanomas usually 
occur in occult sites, which in combination with the lack of early specific 
signs contributes to the delay in diagnosis and poor prognosis of the 
disease. Given the rarity of mucosal melanomas, knowledge about their 
pathogenesis and risk factors is insufficient and when compared with 
cutaneous and ocular melanoma, they have the lowest five-year sur-
vival rate. Surgical resection is frequently the first approach to primary 
tumors, even though the utility of lymph node surgery and radiation 
therapy is not well established. Novel molecular techniques such as 
whole exome sequencing have become routine in order to aid patient 
care. They show great promise in the treatment of rare and usually fa-
tal diseases such as mucosal melanomas. Target therapy against c-KIT 
activating mutations, frequently seen in mucosal melanomas, and the 
immunotherapy have emerged as a promising treatment modality for 
these aggressive tumors.
KEY WORDS: mucosal melanoma, melanoma epidemiology, mucosal 
melanoma management
INTRODUCTION
Mucosal melanoma (MM) is a rare form of malig-
nant melanoma, representing 1% of melanoma cases 
(1), with a five-year survival rate of 25% as opposed 
to approximately 80% in cutaneous melanomas (1,2). 
This variant of malignant melanoma mainly affects 
the head and neck, followed by anorectal and vulvo-
vaginal mucosa, in order of prevalence (1-3). Some 
authors are extremely adamant that in MM, such as 
oral MMs, the disease outcome is invariably fatal de-
spite any treatment (4). On the other hand, other re-
searchers claim that a host of new treatment options 
has been developed for patients with melanoma. De-
spite the lower rates of 5-year survival of MM, com-
pared with cutaneous and ocular melanoma, the re-
cent findings with regards to the molecular changes 
that underlie the development of MMs have offered 
new hope for the development of more effective sys-
temic therapy (5). 
Abbreviations:
AJCC – American Joint Committee on Cancer
CI – Confidence interval
EGFR – Epidermal growth factor receptor
HNMM – Head and neck mucosal melanoma
HR – Hazard ratio
MM – Mucosal melanoma
OMM – Oral mucosal melanoma
SMM – Sinonasal mucosal melanoma 
TEAM – Tasigna® Efficacy in Advanced Melanoma
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EPIDEMIOLOGY
Incidence of MM is higher in women than in men, 
mostly due to female genital tract melanomas. The 
incidence increases with age, with more than 2/3 
of patients being older than 60 years of age. The 
disease is more frequent among whites than blacks 
(2). A large recent analyses comprising almost five 
hundred patients from 15 skin cancer centers in Ger-
many with histologically confirmed diagnosis report-
ed that the most common site of MM was the head 
and neck region, in agreement with the literature 
(1-5), followed by the female genital tract and ano-
rectal region (7). Conversely, in Asia with up to 25% 
incidence MM represents the second most common 
subtype of melanoma, after acral melanoma; gastro-
intestinal melanomas, specifically at the lower tract, 
represent almost 26% of cases of MM (8).  
ETIOPATHOGENESIS
Unlike cutaneous melanomas, MM is not associ-
ated with ultraviolet radiation exposure, and the fact 
that genetic mutations are variable among different 
types of MM suggests that melanoma subtypes differ 
not only clinically but also biologically (1). MM origi-
nates from melanocytes that have migrated from the 
neural crest, although it is becoming clear that mela-
noma is not just a single disease, but rather a family 
of diseases characterized by particular molecular ab-
normalities. In that context, MM represents a unique 
subgroup in this emerging molecular classification 
system, which has tremendous implications for the 
development of new and effective therapies for pa-
tients with MM and will be addressed in detail below 
(9). 
DIAGNOSIS
It is of paramount importance to exclude the pos-
sibility of metastatic lesions from primary cutaneous 
melanoma, especially on sites where they rarely pres-
ents as a primary MM (2). Due to the highly variable 
clinical presentation of MM and areas of occurrence 
that are difficult to access during physical examina-
tion, it is frequently confused with other conditions, 
leading to disease progression being at an advanced 
stage by the time diagnosis is confirmed by biopsy 
(1). MMs of the head and neck are usually flat, but 
may be elevated when present in the oral cavity, al-
though they are usually polypoid or seen as poorly 
defined masses when detected in the sinonasal area. 
Vulvovaginal MM are also usually polypoid but nev-
ertheless may present as satellite lesions or nevi (3). 
When a diagnosis of mucosal melanoma is confirmed, 
it is essential to exclude the regression of a previous 
melanoma and cutaneous or eye melanoma metas-
tasis, reinforcing the importance of dermatologic 
and ophthalmologic follow-up of these patients even 
with no previous history of the disease (1). 
Staging
According to the literature, a specific TNM classi-
fication is available only for skin and ocular lesions, 
and there is a simple system for HNMM is based on 
3 stages, namely stage I: MM limited to primary site; 
stage II: MM with neck lymph node metastasis; and 
stage III: MM with distant metastasis (5). Neverthe-
less, the new TNM classification includes malignant 
melanomas of upper aerodigestive tract. This classifi-
cation applies only to HNMM. However, Ballester Sán-
chez et al. consider the Ballantyne simplified staging 
system applicable to all MM, only extending stage II 
to regional lymph node involvement instead of the 
neck lymph nodes (1).
Given that MM are aggressive tumors, T1 and T2 
are omitted and the primary tumor classification skips 
from T0, where there is no evidence of primary tumor, 
to a mucosal disease (T3) with the tumor limited to the 
epithelium and/or submucosa, followed by T4 when 
moderately advanced or very advanced disease is 
present. T4a indicates moderately advanced disease 
with tumor involving deep soft tissue, cartilage bone 
or overlying skin; T4b indicates very advance disease, 
with the tumor involving the brain, dura, skull base, 
lower cranial nerves, masticator space, carotid artery, 
prevertebral space, or mediastinal structures (10). 
Implementation of appropriate staging systems for 
other locations of MM is required to provide not only 
adequate staging, but also treatment planning and 
prognostication for patients (2). Further data regard-
ing melanoma staging was published by the AJCC 
(11), even though MM is not specifically mentioned 
(12).
Mucosal melanoma of the head and neck
HNMM are uncommon malignancies that arise 
mainly in the nasal cavity and paranasal sinuses, fol-
lowed by the oral cavity (9). The incidence of OMM 
is higher in Japanese than in Caucasians patients, 
with Japanese patients representing up to 8% of all 
malignant melanomas. Upper gingival and palatal 
mucosae are the most commonly affected sites (13). 
Immunohistochemical staining PD-L1 in MM was not 
correlated with age, sex, or anatomical localization 
of the tumor. Interestingly, patients with PD-L1-posi-
tive HNMM had a significantly longer recurrence-free 
survival (P=0.026). In contrast to cutaneous melano-
ma and some other malignancies, a relevant PD-L1 
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overexpression in MM of the head and neck could 
not be confirmed (14).
Due to the rarity of sinonasal mucosal melanoma 
(SMM), prospective studies are not available in the 
literature. SMM show poor prognosis due to high 
metastatic potential requiring wide resection as main 
treatment modality, with adjuvant radiotherapy to 
improve local control (15). Incidence of SMM in the 
nasal cavity is increasing, especially in Caucasian 
women in the USA, and retrospective studies reveal 
a poor prognosis (15,16).
Mucosal melanoma of the anorectal area
Anorectal mucosal melanomas have been associ-
ated with the poorest prognosis of all mucosal mela-
nomas sub-regions and could benefit strongly from 
screening efforts in order to establish an earlier diag-
nosis and improve survival rates after treatment (7). 
Mucosal melanoma of the vulvovaginal 
area
Mucosal melanoma of the vulva and vagina are 
normally diagnosed at the labia, vagina, urethra, or 
cervix and present as aggressive tumors with the 
clinical aspect of a mass, normally accompanied by 
pain, bleeding, or itching, and less commonly dysuria 
or ulceration (3).
Mucosal melanoma in unusual locations
In theory, MM can occur in any mucosal lining of 
the human body. A small amount of MM cases have 
been described in less common sites, such as the 
male urethra, the bladder, the esophagus, and other 
parts of the intestine (1).
MUCOSAL MELANOMA TREATMENT
Free margin resection of the tumors is gener-
ally difficult due to the complicated location of the 
lesions and the multifocal nature of the disease (1). 
Surgical resection is frequently the first approach to 
primary tumors, even though the utility of lymph 
node surgery and radiation therapy is not well estab-
lished (3). Nevertheless, radiotherapy may be used as 
an adjuvant treatment; in cases where lesions are un-
resectable, definitive radiotherapy could be consid-
ered. Despite aggressive locoregional management, 
recurrent disease is common and treatment remains 
challenging (17). Novel molecular techniques such 
as whole exome sequencing have become routine in 
order to aid patient care and show great promise in 
treatment of rare and usually fatal diseases such as 
mucosal melanomas.
A systematic review with meta-analyses of upper 
airways tract MM treatment revealed that surgical 
resection with postoperative radiotherapy remains 
the gold standard for locoregional control. No studies 
investigated quality of life, treatment-related mortal-
ity, or morbidity. Furthermore, their results indicated 
that the addition of radiotherapy to surgery reduces 
the rate of locoregional recurrence (HR, 0.50; 95% CI, 
0.42-0.87). Since there was no statistically significant 
difference in overall survival (HR, 1.16; 95% CI, 0.98-
1.37), more robust studies are needed to determine 
the usefulness of target therapy (after proper valida-
tion) in improving overall survival (18).
Targeted therapy for mucosal melanoma
In a recent study, SMM howed high expression of 
HER4 (70.3%), a member of EGFR family, which also 
was correlated to a high CD44 immunopositivity 
(65.6%) and suggests that molecular target therapy 
for HER4 in SMM might be beneficial. Indeed, HER4 
and CD44 expression indicate that HER4 positivity 
might be an important factor in valuing the prog-
nosis of patients with the disease (19), even though 
further molecular studies are required to clarify the 
tumor profile, its microenvironment, and immune 
compartment.
c-KIT aberrations are relatively common in MM, 
potentially leading to an eminent role of c-KIT inhibi-
tors such as imatinib, sunitinib, dasatinib, nilotinib, 
and masitinib. Nilotinib (NCT01099514) and masitinib 
(NCT01280565) are in clinical trials for patients with 
advanced melanomas who have c-KIT mutations. A 
single-arm, phase II Tasigna® Efficacy in Advanced 
Melanoma (TEAM) trial evaluated the KIT-selective 
tyrosine kinase inhibitor in patients without prior 
KIT inhibitor treatment. Ten of the eleven respond-
ing patients had exon 11 mutation, suggesting that 
nilotinib may be an effective treatment option for 
patients with specific KIT mutations (20). The combi-
nation of dabrafenib and trametinib or vemurafenib 
with cobimetinib are FDA approved for primary and 
metastatic melanomas harboring specific activating 
mutations in the BRAF kinase domain. Nevertheless, 
the low prevalence of BRAF mutations in mucosal 
melanomas reduces the utility of these new treat-
ments, which is likely to be limited to a small subset 
of patients (3).
NRAS gain was recently evaluated in acral, muco-
sal, chronic sun-induced damage (CSD), and non-CSD 
melanomas in China, with an overall incidence of 
14%. Surprisingly, MMs presented a 15.8% incidence 
(6). NRAS mutations are not usually reported in MMs, 
even though Heppt et al. found a similar incidence 
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of NRAS mutations (13.8%) in Germany, and the af-
fected patients can benefit from target therapy with 
binimetinib, pending clinical trial validation (7). 
Heppt et al. demonstrated that NRAS (13.8%), KIT 
(8.6%), and BRAF (6.4%) mutations were evenly dis-
tributed amongst 444 tumors within all MM groups 
(7). NRAS mutations in esophageal melanomas, a very 
unusual site even for MM, were detected at a higher 
percentage than in cutaneous melanomas (21). Even 
though the case series only included 16 melanomas 
of the esophagus, this result reinforces the impor-
tance of approaching the tumors in an individual ba-
sis, in the context of personalized medicine.
Employing an immunotherapy approach, such as 
involving anti-PD-1 agents, is supported by scientific 
evidence, not only in mucosal but also in acral mela-
nomas. Recently, response rates to PD-1 blockade in 
patients with acral and MMs were slightly lower but 
comparable to response rates in cutaneous melano-
mas and support the routine use of anti-PD-1 agents 
for MM (22).
Prognostic factors and treatment out-
comes
Several independent risk factors for disease pro-
gression have to be considered, such as male gender 
(P=0.047), advanced tumor stage (P=0.001), nodal 
disease (P=0.001), and incomplete resection sta-
tus (P=0.001). Female genital tract MMs present the 
highest overall survival (P=0.030), along with patients 
without ulceration (P=0.004). Multivariate risk factors 
for overall survival are metastasis stage at diagnosis 
(P=0.002) and incomplete resection of the primary 
tumor (P=0.001). As previously mentioned, anorectal 
melanomas are associated with the poorest progno-
sis among all MM (7). Screening for NRAS, KIT, and 
BRAF mutations in MM might prove beneficial in the 
near future, although solid evidence regarding their 
real potential as well as new targeted therapies in cu-
taneous melanomas are lacking (15).
The future in mucosal melanoma research 
and treatment
Next generation sequencing is a bioinformatics 
tool that is becoming highly integrated in cancer 
research. Sequencing data is becoming widely avail-
able, and the further efforts in analysis should focus 
on individual mutations or structural variants when 
the main driver mutations or structural variants are 
absent in the melanoma sample. Single-cell RNA 
sequencing could also be applied to longitudinal 
melanoma samples under therapy. Analysis of these 
samples would simultaneously reveal the phenotypic 
expression changes from the therapy in both the mi-
croenvironment and immune compartment, apart 
from the tumor itself. These data would be useful for 
discovering cell autonomous resistance mechanisms 
and non-cell autonomous resistance mechanisms 
from the same sample. 
The advent of bioinformatics analysis provides rel-
evant information that can be used for treatment in a 
personalized medicine setting. As sequencing costs 
decrease and algorithms become better at predict-
ing epitope binding and T-cell receptor recognition, 
it could become possible to provide many melanoma 
patients with a personalized immunization therapy 
for their tumor. Interdisciplinary teams of cancer bi-
ologists, immunologists, bioinformaticians, and clini-
cians will have to work together to drive melanoma 
research and treatment forward (23).
CONCLUSION
This review pinpointed several burdens related to 
malignant MM epidemiology, ranging from difficul-
ties in treatment to late diagnosis of the disease. Re-
sidual primary lesions, positive cervical lymph nodes, 
and c-Kit mutations act as adverse prognostic factors 
for metastatic OMMs. The kit inhibitor imatinib could 
benefit metastatic patients presenting c-Kit muta-
tions (24,25). Scientific evidence for treatment choice 
in other types of MMs is poor, and immunotherapy 
has emerged as a promising treatment modality for 
these aggressive tumors.
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